Three New Targets Found for Cancer Vaccines
Ludwig Cancer ResearchInvestigators at the Ludwig Institute for Cancer Research have discovered three new genes that may prompt the immune system to seek out and destroy cancer cells.
Investigators at the Ludwig Institute for Cancer Research have discovered three new genes that may prompt the immune system to seek out and destroy cancer cells.
Phase I study suggests that a protein-based vaccine may safely activate anti-cancer defenses.
Researchers discovered that chromosome 21 contains 10% more genes than earlier sequence efforts found, suggesting that if predictions on the smallest and most thoroughly analyzed chromosome are wrong, than humans have more genes than the favored 30,000 estimate.
Study suggests that current DNA chips need improvement to fully understand how genes work.
Experts who utilize gene databases on the Internet face the same type of problems that greet many Web surfers, so some of them have designed an easier and more accurate way to search for potential disease-causing genes.
Study in mice suggests that blocking one signaling pathway may help against autoimmune disease, transplant rejection, and leukemia.
In a step that might eventually make colon cancer easier to detect and treat, a study finds that the immune system naturally identifies the hallmark signs of this cancer.
A novel video technique exposes an unnoticed pathway that allows dormant immune cells to become active again, providing new insights on how the immune system might be harnessed to fight disease.
For the first time, investigators from six local New York medical centers are all working together to conduct a series of unique early-stage clinical trials on cancer vaccines.
A protein that hinders tumor fighting genes may be the key to new treatments for cancer.
Brazilian researchers decipher genetic clues that may spell the end of a pest that threatens Californian wine.
A study explains how cells crucial to the body's defense system can stimulate an immune response, raising new possibilities for their use in cancer vaccines.
Researchers find that the bioluminescence effects of fireflies may kill cancer cells from within.
A study pushes the Human Genome Project one step forward, documenting the complete activity of genes found in both healthy and cancerous cells.
Researchers study a range of vaccine strategies to harness the body's own natural ability to fight cancer. One patient seemingly helped by immune defenses alone.
Can the complete genetic sequence of a common bacterium found in the Amazon help save the rainforest?
First study to demonstrate that vaccination with a cancer-specific recombinant protein antigen has successfully induced a fully integrated immunological response in humans.
Discovery of novel protein processing mechanism, proteasome-mediated post-translational splicing of peptides, which has implications for predicting protein sequence from gene sequence, and for monitoring immunological responses to cancer, and perhaps HIV, vaccines.
Scientists from the Cancer Vaccine Collaborative (CVC) have discovered that the cancer-specific protein, SSX-2, induces a spontaneous immunological reaction against cancer cells in melanoma patients, offering a new target for the development of a therapeutic melanoma vaccine.
Investigators analyzed the function of CD8 T cells that recognize a cancer-specific antigen and found that the tumor and invaded lymph nodes are able to neutralize the function of cytotoxic CD8 T cells.
While insights into breast cancer have been drawn from determining the expression 'profiles' of thousands of genes in tumors, the interpretation of experimental results has been complicated by the absence of knowledge about the gene expression in 'normal,' non-cancerous, breast cells.
Just weeks after one of the first anti-EGFR antibodies, ImClone's Erbitux (Cetuximab), was approved for use in Europe and the USA, the unique binding properties of a "˜second generation' anti-EGFR antibody from LICR have been elucidated.
A therapeutic cancer vaccine being co-developed by the Ludwig Institute for Cancer Research and the Australian biotechnology company CSL Limited successfully induced a comprehensive immune response in patients and appeared to delay cancer recurrence.
New findings in the development of cancer vaccines from the USA, Australia, Europe and Japan will be presented as part of the International Cancer Immunotherapy Symposia Series.
Findings from the University College London Branch of the Ludwig Institute for Cancer Research detail how inactivating a key signalling molecule called p110delta reduced the effect of allergies on mice.
Results from the first clinical trial of a therapeutic cancer vaccine combining the synthetic bacterial DNA sequence, CpG 7909, with a peptide antigen were reported.
Scientists at the University of California, San Diego Branch of the Ludwig Institute for Cancer Research have identified a key network of DNA repair and cell cycle control genes in yeast that prevents the deleterious effects of radical oxygen species.
Levels of the Smad7 protein may predict therapeutic response in patients with prostate cancer according to research published today by investigators at the Uppsala Branch of the Ludwig Institute for Cancer Research (LICR).
A team of investigators from the Uppsala Branch of the Ludwig Institute for Cancer Research and Harvard Medical School has uncovered novel targets for the development of drugs that would potentially complement, or replace, statins in treating heart disease.
Investigators have developed an efficient method to identify thousands of regulatory sequences in the human genome, according to a study.
A multi-national research team led by the Melbourne Branch of the Ludwig Institute for Cancer Research has identified a potential new target for stomach cancer therapy, according to a paper published today.
A study in Nature has defined the function of p110 alpha PI3K, which is in one of the most frequently activated pathways in cancer. Using a new approach to generating mouse models investigators from the Ludwig Institute for Cancer Research and the UCL Centre for Diabetes & Endocrinology have uncovered important information for planned clinical trials.
Colinearity of DNA and protein sequences is thought to be a fundamental feature of the universal genetic code. However, a paper published today in Science by a team from the Brussels Branch of the global Ludwig Institute for Cancer Research (LICR) and the Seattle-based Fred Hutchinson Cancer Research Center (FHCRC), shows that a protein can be rearranged so that it is no longer colinear with its encoding DNA.
Three Ludwig scientists were named as Fellows in the inaugural class of the AACR Academy, the most prestigious honor bestowed by the American Association for Cancer Research. The 106 Fellows were selected by their peers for their extraordinary contributions to the cancer field.
In the current issue of Cancer Discovery, a team led by Paul Mischel at the Ludwig Institute for Cancer Research and Steven Bensinger at the University of California, Los Angeles, identifies a unique mechanism by which glioblastoma cells develop resistance to drugs that target EGFR signaling.
A dozen Ludwig scientists presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research Annual Meeting. Progress in immunotherapy and epigenetics led the program with important treatment implications for emerging cancer therapy.
A recent study published by Ludwig scientists in Nature upends the model for how dividing cells monitor the equal distribution of their chromosomes—a process that often runs awry in cancer. By targeting Aurora B kinase, their discovery has overturned the prevailing model of advanced cell division.
Cancer cells are a problem for the body because they multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong. One protein that keeps healthy cells from behaving this way is a tumor suppressor named p53. This protein stops potentially precancerous cells from dividing and induces suicide in those that are damaged beyond repair. Not surprisingly, p53’s critical function is disrupted in most cancers.
A large, multi-institutional research team involved in the NIH Epigenome Roadmap Project has published a sweeping analysis in the current issue of the journal Cell of how genes are turned on and off to direct early human development.
Professor Sir David Lane, an internationally recognized and respected cancer researcher widely known for his discovery of the p53 tumor suppressor protein, joins the Ludwig Institute for Cancer Research as its Scientific Director, commencing June 1, 2013.
A team of researchers led by Jedd Wolchok of the Ludwig Center at MSKCC presented data today at the ASCO Annual Meeting showing promising results from a Phase I clinical trial evaluating the concurrent use of two immunotherapies for the treatment of advanced melanoma.
The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and Immune Design, a biotech company focused on immune-based therapies for cancer and other human diseases, today announced that they have signed a collaboration agreement to advance cancer immunotherapy research.
An international team of scientists led jointly by the Ludwig Institute for Cancer Research and the University of Murcia describe a therapeutic strategy in today’s online issue of Cancer Cell that manipulates a mechanism driving cellular heterogeneity to treat advanced melanoma.
Loss of a gene required for stem cells in the brain to turn into neurons may underlie the most severe forms of neuroblastoma, a deadly childhood cancer of the nervous system, according to a Ludwig Cancer Research study published in Developmental Cell today.
A team of researchers affiliated with Ludwig Cancer Research and the Karolinska Institutet in Sweden report in the current issue of Nature Methods a dramatically improved technique for analyzing the genes expressed within a single cell—a capability of relevance to everything from basic research to future cancer diagnostics.
A Ludwig Cancer Research study published in Cell today identifies a common mutation that dramatically increases the risk for testicular cancer—and describes a likely molecular mechanism by which it exerts that effect.
Ludwig Cancer Researchers find that glioblastomas that rely predominantly on the mTORC2-mediated pathway tend to have the worse prognosis. Further, their studies suggest that lung cancer cells, too, use this pathway to induce the Warburg effect.
A new technique successfully takes on a longstanding challenge in DNA sequencing – determining whether a particular genetic sequence comes from an individual's mother or father. The method, described in a Ludwig Cancer Research study in Nature Biotechnology, promises to accelerate studies of how genes contribute to disease, improve the process of matching donors with organs and help scientists better understand human migration patterns.
A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma (GBM), the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer. The findings could have far-reaching implications for the therapeutic regimens currently employed to treat GBM and suggest alternative approaches that could improve outcomes for cancer patients.
Cancer research in the U.S. got a critical boost today as the six Ludwig Centers at Johns Hopkins University, Harvard University, the Massachusetts Institute of Technology, Memorial Sloan-Kettering Cancer Center, Stanford University and the University of Chicago received a total of $540 million as part of a gift from Ludwig Cancer Research, on behalf of its founder, Daniel K. Ludwig. This new funding ranks among the largest private philanthropic gifts to cancer research.